Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.

Apremilast may be a promising long-term treatment for hidradenitis suppurativa.

NXC736 significantly reduced hair loss in mice with alopecia areata.

Upadacitinib may cause hair loss.

Denosumab treatment for osteoporosis can cause hair loss.

Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.

Alitretinoin may help treat mild to moderate alopecia areata.

Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.

Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.

Dutasteride microinfusion and microneedling both effectively treat male hair loss.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

Upadacitinib successfully treated a child's severe skin and hair loss issues.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.

Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.

A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.

A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.

ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

Infliximab may cause hair loss in Crohn's disease patients.

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

Early recognition and a team approach are crucial for managing diffuse alveolar hemorrhage in antiphospholipid syndrome.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Baricitinib helps long-term hair regrowth in severe alopecia areata patients.

Tralokinumab effectively improved atopic dermatitis symptoms in most patients, but some stopped due to side effects like hair loss.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

Belimumab effectively controls SLE disease activity and reduces steroid use.

Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.